Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 28, 2026
TickeronGET DAILY SIGNALS
ALXO vs AXON: Biotech Catalyst Risk Against a De-Rated Growth Stock Down Over 50% from Peak

ALXO vs AXON: Biotech Catalyst Risk Against a De-Rated Growth Stock Down Over 50% from Peak

Key Takeaways

  • ALXO is a clinical-stage, pre-revenue immuno-oncology biotech, while AXON is a profitable, fast-growing public-safety technology company — a stark contrast in business maturity and risk profile.
  • Axon generates strong recurring revenue, with annual recurring revenue (ARR) up 39% to roughly $1.6 billion, while ALX Oncology reports no product revenue and relies on cash runway and clinical catalysts.
  • AXON has been repriced sharply lower in recent months — down more than 50% from its 2025 peak — despite continued revenue growth, while ALXO trades near multi-year lows with a small market capitalization.
  • ALXO's valuation hinges on binary clinical-trial outcomes for its lead drug evorpacept, whereas AXON's story centers on execution, margin compression, and valuation reset in a premium-growth stock.
  • Analyst consensus is "Strong Buy" for ALXO and "Buy" for AXON, though the two ratings reflect very different underlying risk and reward frameworks.
  • Investors can track more details on ALXO Major News and ALXO Today's Price Move, as well as AXON Major News and AXON Today's Price Move, for timely updates on each name.
  • For automated, data-driven market analysis, explore Trending AI Robots to see which strategies are currently favored by AI trading systems.

Setting the Stage

Comparing ALXO (ALX Oncology Holdings) and AXON (Axon Enterprise) is, in many ways, a study in opposites. One is a small, clinical-stage biotechnology company with no product revenue whose fortunes depend on drug-trial data; the other is a multi-billion-dollar, revenue-generating leader in public-safety technology and software. This stock comparison is most relevant for investors weighing high-risk, catalyst-driven biotech exposure against a growth company undergoing a valuation reset. Both names have experienced meaningful volatility in recent market activity, making their relative performance and market positioning a useful lens for traders and longer-term investors alike. I also checked this using Tickeron’s AI Screener to see how the two names stack up against peers.

ALXO Overview and Recent Performance

ALX Oncology Holdings is a clinical-stage immuno-oncology company focused on therapies for cancer patients. Its lead candidate, evorpacept, is a CD47-blocking therapeutic (a drug that blocks a "don't eat me" signal used by cancer cells to evade the immune system), and it is being studied in combination with other anti-cancer agents across multiple tumor types. A second candidate, ALX2004, is an EGFR-targeted antibody-drug conjugate (ADC), a therapy that delivers a toxic payload directly to cancer cells.

In recent weeks, sentiment around ALXO has been shaped primarily by clinical data. Management presented results showing that evorpacept combined with zanidatamab produced durable responses in heavily pre-treated HER2-positive breast cancer patients, particularly those with high CD47 expression. The company has also received FDA Fast Track designations (a designation that can accelerate drug review) for evorpacept in certain indications. Despite these signals, the stock trades near its 52-week lows with a market capitalization well under $200 million, reflecting both the company's pre-revenue status and the binary risk inherent in clinical-stage biotech. Analyst consensus remains "Strong Buy," but the path to value realization depends heavily on upcoming trial readouts and regulatory progress.

AXON Overview and Recent Performance

Axon Enterprise is a public-safety technology company best known for its TASER conducted electrical weapons and body cameras, alongside a growing software and AI platform that includes evidence management, records tools, and counter-drone (Dedrone) capabilities. The company has evolved from a hardware maker into a recurring-software business, with annual recurring revenue (ARR) up 39% to about $1.6 billion and net revenue retention near 126%.

Recent market activity for AXON has been volatile. The shares have declined more than 50% from their 2025 peak and are down roughly 25% year-to-date, even as the company reported quarterly revenue of approximately $904 million (up about 35% year over year) and raised its full-year outlook. A five-day winning streak in late October, tied partly to the unveiling of the Axon Body 5 camera, trimmed some losses. Weighing on sentiment have been concerns about margin compression, a $1 billion convertible-note offering, and the premium valuation that the stock carried at its highs. Consensus is a "Buy" with an average price target well above the current price. From what I see, the recent pullback has created an interesting setup worth monitoring closely.

Head-to-Head Comparison

The contrasts between these two companies are fundamental. ALXO operates in biotechnology with a concentrated, binary risk profile: its near-term value is tied almost entirely to evorpacept's clinical outcomes and the company's cash runway, which funds operations without product revenue. Its sector exposure is to oncology drug development, where catalysts such as trial data and FDA decisions drive sharp, event-based price moves.

AXON, by contrast, has a diversified hardware-plus-software model with proven, growing revenue and a strong balance-sheet trajectory. Its growth drivers include AI adoption in public-safety workflows, international expansion, and newer categories like counter-drone technology. Its risks are more execution- and valuation-related: government budget dependence, margin compression during an investment cycle, and the challenge of sustaining premium growth rates. In terms of momentum, AXON has recently shown short-term stabilization after a prolonged drawdown, while ALXO remains in a lower-volatility but fundamentally speculative trading range. For a stock comparison, the trade-off is essentially between a catalyst-driven, high-upside micro-cap and a de-rated but fundamentally profitable growth company.

Tickeron AI Verdict

Based on observable factors, Tickeron's AI would likely favor AXON for trend consistency and stability, given its established revenue base, recurring-software model, and emerging short-term momentum after a deep correction. ALXO's profile is more speculative, with value tied to binary clinical catalysts that AI models typically assess as higher-uncertainty. That said, ALXO's recent positive biomarker data and "Strong Buy" analyst consensus suggest meaningful upside potential if clinical milestones are met. The probabilistic view, therefore, leans toward AXON for relative stability and demonstrated fundamentals, while acknowledging ALXO as a higher-risk, higher-reward candidate whose outcome depends on trial results. I also checked this using Tickeron’s AI Trend Prediction Engine to gauge longer-term signals.

Exploring AI Trading Strategies

In my own work, I regularly look at Tickeron’s AI Trading Bots to understand how different automated approaches are performing across market regimes. These tools let me compare strategies side by side without having to build everything from scratch, which helps keep the analysis grounded in current data rather than just narrative.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXON, ALXO

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AXON's RSI Indicator descends into oversold zone

The RSI Indicator for AXON moved into overbought territory on November 20, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +2.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where AXON advanced for three days, in 270 of 367 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

AXON may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AXON as a result. In 52 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.

The Moving Average Convergence Divergence Histogram (MACD) for AXON turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In 27 of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

The 50-day moving average for AXON moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.

The Aroon Indicator for AXON entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 65 (best 1 - 100 worst), indicating fairly steady price growth. AXON’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 82 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AXON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.

The Tickeron Valuation Rating of 90 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.920) is normal, around the industry mean (5.050). AXON has a moderately high P/E Ratio (126.721) as compared to the industry average of (17.247). Projected Growth (PEG Ratio) (1.949) is also within normal values, averaging (3.110). Dividend Yield (0.000) settles around the average of (0.055) among similar stocks. P/S Ratio (12.034) is also within normal values, averaging (18.367).

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 36.83B. The market cap for tickers in the group ranges from 4.49 to 1.77T. SPCX holds the highest valuation in this group at 1.77T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was -16%. For the same Industry, the average monthly price growth was -17%, and the average quarterly price growth was -35%. POWW experienced the highest price growth at 13%, while VWAV experienced the biggest fall at -55%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 41%. For the same stocks of the Industry, the average monthly volume growth was 16% and the average quarterly volume growth was -22%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 53
Price Growth Rating: 65
SMR Rating: 78
Profit Risk Rating: 79
Seasonality Score: -14 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company

Industry AerospaceDefense

Industry
Biotechnology
Address
17800 North 85th Street
Phone
+1 480 991-0797
Employees
6300
Web
https://www.axon.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.